ArticleCureus2024
Gastrointestinal Basidiobolomycosis: A Case Series.
Article in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 4 citations in OpenAlex.
- Clinical consequences of delayed recognition of gastrointestinal basidiobolomycosis: a case series.Journal of surgical case reports · 2026Article
- Liposomal amphotericin B in the treatment of pediatric gastrointestinal basidiobolomycosis.Journal of medical case reports · 2026Article
- Abdominal defect reconstruction due to advanced lobomycosis with anterolateral thigh (alt) flap: a case report.Case reports in plastic surgery & hand surgery · 2026Article
- Gastrointestinal Basidiobolomycosis Mimicking Adhesive Bowel Disease and Ileocaecal Malignancy in an Adult HIV Patient: A Case Report Highlighting a Diagnostic Pitfall.International medical case reports journal · 2026Article
- When Eosinophils Mislead: Gastrointestinal Basidiobolomycosis Initially Misdiagnosed as Eosinophilic Colitis.European journal of case reports in internal medicine · 2026Article
- Ileocecal basidiobolomycosis mimicking malignancy successfully treated without surgery: A case report.World journal of clinical cases · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastrointestinal basidiobolomycosis (GIB) is a rare fungal infection caused by Basidiobolus ranarum, a saprophytic fungus that belongs to the class of Basidiobolomycetes. It mainly infects immunocompetent individuals and is mainly found in arid tropical and subtropical regions, including Southwestern America, Saudi Arabia, Africa, and Asia. Not surprisingly, a great number of human infections have been reported from these warm, humid climate regions that are felicitous for the growth of this fungus, especially from the southern region of Saudi Arabia and Arizona in the United States of America. GIB is easily misdiagnosed as malignancy, inflammatory bowel disease, diverticulitis, lymphoma, and chronic intestinal infections due to its rarity. In this case series, we summarize the clinical features, imaging, histopathological features, and treatment of patients diagnosed with GIB in our institution.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.